Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;30(6):849-900.
doi: 10.1080/13854046.2016.1202239.

Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders

Affiliations
Review

Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders

Erin E Robertson et al. Clin Neuropsychol. 2016 Aug.

Abstract

Objective: The purpose of this paper is to review the typical cognitive and motor impairments seen in fragile X-associated tremor/ataxia syndrome (FXTAS), essential tremor (ET), Parkinson disease (PD), spinocerebellar ataxias (SCAs), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) in order to enhance diagnosis of FXTAS patients.

Methods: We compared the cognitive and motor phenotypes of FXTAS with each of these other movement disorders. Relevant neuropathological and neuroimaging findings are also reviewed. Finally, we describe the differences in age of onset, disease severity, progression rates, and average lifespan in FXTAS compared to ET, PD, SCAs, MSA, and PSP. We conclude with a flow chart algorithm to guide the clinician in the differential diagnosis of FXTAS.

Results: By comparing the cognitive and motor phenotypes of FXTAS with the phenotypes of ET, PD, SCAs, MSA, and PSP we have clarified potential symptom overlap while elucidating factors that make these disorders unique from one another. In summary, the clinician should consider a FXTAS diagnosis and testing for the Fragile X mental retardation 1 (FMR1) gene premutation if a patient over the age of 50 (1) presents with cerebellar ataxia and/or intention tremor with mild parkinsonism, (2) has the middle cerebellar peduncle (MCP) sign, global cerebellar and cerebral atrophy, and/or subcortical white matter lesions on MRI, or (3) has a family history of fragile X related disorders, intellectual disability, autism, premature ovarian failure and has neurological signs consistent with FXTAS. Peripheral neuropathy, executive function deficits, anxiety, or depression are supportive of the diagnosis.

Conclusions: Distinct profiles in the cognitive and motor domains between these movement disorders may guide practitioners in the differential diagnosis process and ultimately lead to better medical management of FXTAS patients.

Keywords: FXTAS; Parkinson disease; essential tremor; multiple system atrophy; progressive supranuclear palsy; spinocerebellar ataxia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Differential diagnosis of FXTAS
Key: FXTAS, fragile X associated tremor/ataxia syndrome; ET, essential tremor; PD, Parkinson’s syndrome; SCA, spinocerebellar ataxia; MSA, multiple system atrophy; PSP, progressive supranuclear palsy. * This refers to the early-onset subtype of ET (Deuschl, 2009). ** This refers to the late-onset subtype of ET, which is more likely to be confused with FXTAS (Deuschl, 2009). *** Also inquire regarding a FH of autism, developmental delay, or learning disabilities. **** Cerebellar eye signs include nystagmus, saccadic pursuits, and slowed saccades. If the patient has ataxia and prominent kinetic tremor, consider SCA12.

References

    1. Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, & Larsen JP (2009). The spectrum of neuropsychiatric symptoms in patients with early untreated parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 80(8), 928–930. doi:10.1136/jnnp.2008.166959 [doi] - DOI - PubMed
    1. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, … Emre M (2010). Mild cognitive impairment in parkinson disease: A multicenter pooled analysis. Neurology, 75(12), 1062–1069. doi:10.1212/WNL.0b013e3181f39d0e [doi] - DOI - PMC - PubMed
    1. Aarsland D, & Kramberger MG (2015). Neuropsychiatric symptoms in parkinson’s disease. Journal of Parkinson’s Disease, 5(3), 659–667. doi:10.3233/JPD-150604 [doi] - DOI - PubMed
    1. Aarsland D, Larsen JP, Cummins JL, & Laake K (1999). Prevalence and clinical correlates of psychotic symptoms in parkinson disease: A community-based study. Archives of Neurology, 56(5), 595–601. - PubMed
    1. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, & Cummings JL (1999). Range of neuropsychiatric disturbances in patients with parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 67(4), 492–496. - PMC - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources